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Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor that controls
expression of genes involved in lipid metabolism and is activated by fatty acids and
hypolipidemic fibrates. Fibrates induce the hepatic expression of murine multidrug
resistance 2 (Mdr2), encoding the canalicular phospholipid translocator. The physiological
role of PPARα in regulation of Mdr2 and other genes involved in bile formation is unknown.
We found no differences in hepatic expression of the ABC transporter genes Mdr2, Bsep
(bile salt export pump), Mdr1a/1b, Abca1 and Abcg5/Abcg8 (implicated in cholesterol
transport), the bile salt uptake systems Ntcp (Na+-taurocholate co-transporting polypeptide
gene) and Oatp1 (organic anion-transporting polypeptide 1 gene) or in bile formation
between wild-type and Pparα (-/-) mice. Upon treatment of wild-type mice with ciprofibrate
(0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and
Mdr1b (+11-fold) mRNA was clearly induced while that of Oatp1 (-5-fold) was reduced.
Mdr2 protein levels were increased, whereas Bsep, Ntcp and Oatp1 were drastically
decreased. Exposure of cultured wild-type mouse hepatocytes to PPARα-agonists
specifically induced Mdr2 mRNA levels and did not affect expression of Mdr1a/b. Altered
transporter expression in fibrate-treated wild-type mice was associated with a ~400 %
increase in bile flow: secretion of phospholipids and cholesterol was increased only during
high bile salt infusions. No fibrate effects were observed in Pparα (-/-) mice. In conclusion,
our results show that basal bile formation is not affected by PPARα deficiency in mice.
The induction of Mdr2 mRNA and Mdr2 protein levels by fibrates is mediated by PPARα,
while the induction of Mdr1a/b in vivo probably reflects a secondary phenomenon related
to chronic PPARα-activation.
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INTRODUCTION
Bile formation critically depends on active secretion of osmotically active compounds
from the liver into the bile canalicular lumen. Several transporter proteins at the hepatocyte
canalicular membrane are involved in secretion of biliary constituents in an active, ATP-
dependent manner. Bile salts and glutathione provide the major driving force for bile
formation1. The bile salt export pump (Bsep or Abcb11) has been identified as the major
canalicular bile salt transporting protein2, while glutathione is transported by Mrp2 (or
Abcc2)3. Bile salt secretion drives the secretion of phospholipids and cholesterol by as yet
unknown mechanisms4, but only when multidrug resistance 2 (Mdr2) P-glycoprotein (Pgp)
is present. Mdr2 Pgp, encoded by Mdr2 (or Abcb4), is absolutely essential for phospholipid
secretion into bile5. Transporters involved in the actual cholesterol secretion process have
not been identified: a number of ABC transporters, i.e., Abca16 and Abcg5/g87 have recently
been shown to play a role. The B subfamily of ABC transporters contains at least 2 additional
members that are localized to the canalicular domain of hepatocytes in rodents, i.e., Mdr1a
(or Abcb1a) and Mdr1b (or Abcb1b). The physiological function of Mdr1a/Mdr1b lies
presumably in hepatobiliary transport of bulky amphiphilic compounds, such as steroids,
hydrophobic peptides and cationic drugs8. High biliary bile salt secretion rates, required
for bile formation and effective dietary lipid absorption, are maintained by effective bile
salt reabsorption from the intestine. Bile salts are taken up from portal blood, prior to
resecretion into bile, by the Na+-taurocholate co-transporting polypeptide (Ntcp; Slc10a1)
and Na+-independent organic anion-transporting polypeptides, including Oatp1 (or
Slc21a1)9.
Insight into the molecular regulation of these transporters is still limited. Bile salts
have been shown to control expression of Bsep10 and Ntcp11 as well as of Mrp212 via
interactions with the recently identified nuclear ‘bile salt receptor’ FXR (farnesoid X
receptor; NR1H4), while hepatic Abca1, Abcg5 and Abcg8 expression is controlled by the
liver X receptor (or NR1H2/3)13,14. Expression of Mdr1b is specifically induced in situations
associated with metabolic stress (inflammation, partial hepatectomy15,16) and appears to
involve NF-κB signalling17. Expression of Mdr2 appears to be controlled in a complex
fashion, as it is induced in rodents by bile salt feeding18, treatment with cholesterol synthesis
inhibitors19,20, insulin deficiency21 and treatment with hypolipidemic fibrates22.
Fibrates exert their metabolic actions via activation of peroxisome proliferator-
activated receptor alpha (PPARα; NR1C1)23,24. Natural ligands of PPARα are (un)saturated
fatty acids and their derivatives. Activated PPARα heterodimerizes with the 9-cis-retinoic
acid receptor (RXR; NR2B1) and alters transcription of target genes after binding to specific
peroxisome proliferator response elements (PPREs). PPARα is highly expressed in the
liver and controls the expression of genes involved in the β-oxidation of fatty acids and
those encoding apolipoprotein A-I, A-II and C-III23,24. Fibrates are widely used in the
treatment of hyperlipidemia: the drugs lower plasma triglycerides and increase HDL-
cholesterol23,25. Fibrates may adversely affect bile composition, as they have been shown
to reduce expression of rate-limiting enzymes in bile salt synthesis26-28. An increased
incidence of cholesterol gallstones in patients undergoing long-term therapy with clofibrate
has been reported29,30.
In rodents, but not in humans, fibrates induce hyperplasia and hypertrophy of
hepatocytes as a consequence of rodent-specific effects on peroxisome proliferation31.
Therefore, earlier data22,32 describing fibrate effects on hepatic transporter expression should
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be interpreted with caution, as they may reflect aspecific consequences of hepatic
hyperplasia. The aim of the present study was to evaluate the role of PPARα in control of
bile formation in mice, with emphasis on its potential role in regulating the expression of
Mdr2 and other hepatic transporter proteins. Therefore, we have studied the effect of fibrates
on the expression of transporter proteins in vitro in cultured mouse hepatocytes and in vivo
in wild-type and Pparα (-/-) SV129 mice.
MATERIALS AND METHODS
Animals
Mice homozygous for disruption of the PPARα gene (Pparα (-/-)) and wild-type (Pparα
(+/+)) mice of the same SV129 background33 were used. Male mice of 25-30 g were housed
in a light- and temperature-controlled facility and received either standard laboratory chow
(Souris AO4, UAR, Lille, France) or the same diet containing 0.05% (w/w) ciprofibrate
for 2 weeks. Food and water were available ad libitum. All experiments were approved by
the ethical committee on animal testing of the University of Groningen, Groningen, The
Netherlands and the Pasteur Institute, Lille, France.
Experimental procedures
After 2 weeks on experimental diets, wild-type and Pparα (-/-) mice (n = 10 per group)
were anesthetized with Hypnorm (1ml/kg) and Diazepam (10 mg/kg). Of each group, six
animals were subjected to gallbladder catheterization to allow collection of bile34. During
the 30 min bile collection period, animals were placed in a humidified incubator to ensure
maintenance of body temperature. Bile flow was determined gravimetrically, assuming a
density of 1 g/ml for bile. Bile was stored at -20°C until analysis. Blood was obtained by
cardiac puncture and the samples were collected in EDTA-containing tubes. Plasma was
obtained by centrifugation in an Eppendorf centrifuge at 15000 g for 10 min (Eppendorf,
Hamburg, Germany) and stored at -80°C until further analysis. The livers were excised,
weighed, cut into small pieces, snap-frozen in liquid nitrogen and stored at -80°C until use
for isolation of membranes for Western blot analysis or for biochemical analyses. From
the other four animals of each group, the livers were also excised, weighed, cut into small
pieces, snap-frozen in liquid nitrogen, and stored at -80°C until use for isolation of RNA.
For microscopic evaluation, small pieces of liver were collected in paraformaldehyde or
in liquid isopentane and stored at -80°C until further use.
In a second experiment, after three basal 10 min bile collections, tauroursodeoxycholate
(TUDC; in 45 mM PBS, pH 7.4) was continuously infused via a jugular vein with the rate
increased in a stepwise manner: 150, 300 and 450 nmol/min for 30 min periods, followed
by 600 nmol/min for 60 min. Bile was collected throughout the experiment at 10 min
intervals.
Mouse hepatocyte isolation and culture
Primary mouse hepatocytes were isolated from male wild-type and Pparα (-/-) mice as
described previously35. The viability of isolated wild-type and Pparα (-/-) hepatocytes was
similar, i.e ~80%. Hepatocytes were suspended in William’s E medium (Gibco BRL, Grand
Island, NY, U.S.A.) supplemented with 10% fetal calf serum, 20 m-units/ml insulin, 50
nM dexamethason, 100 units/ml penicillin, 100 µg/ml streptomycin and 50 µg/ml
gentamycin and seeded on 35 mm six-wells plastic culture dishes (Costar Corp., Cambridge,
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MA, U.S.A.), precoated with collagen (Serva, Feinbiochemica, Heidelberg, Germany) at
a density of 1.0 x 106 cells/well in 2 ml of William’s E medium. After a 5 h attachment
period, the medium was refreshed. After overnight culture, cells were incubated in serum-
free William’s E medium supplemented with 1.7% albumin (fat-free), insulin, penicillin/
streptomcin and gentamycin. After 4 h, ciprofibrate (Sigma, St. Louis, MO, U.S.A.) or
WY14,643 (Alexis, San Diego, CA, USA) dissolved in dimethyl sulfoxide (DMSO) was
added at the indicated concentrations and cells were exposed for the subsequent 24 h. The
cells were maintained in a humidified incubator at 37°C and 5% CO
2
.
Steady-state mRNA levels determined by real-time quantitative PCR
Total RNA was isolated from frozen mouse liver using TRIzol Reagent (Gibco BRL)
according to the manufacturer’s instructions. Total RNA was isolated from cultured
hepatocytes using the SV Total RNA isolation system (Promega, Madison, WI, U.S.A.).
RNA was checked on an agarose gel for integrity and RNA concentration was measured
spectrophotometrically. Single-stranded cDNA was synthesized from 4.5 µg RNA, 30
units Moloney murine leukemia virus (MULV) reverse transcriptase, 6 µl 5-fold
concentrated buffer, 12 units of RNAse inhibitor, 0.406 µg random primer and 3 µl of 10
mM dNTP mix (all from Roche, Mannheim, Germany) in a total volume of 30 µl. Reverse
transcription was performed for 10 min at 25°C and for 1 h at 45°C and the samples were
subsequently heated for 5 min at 95°C to terminate the reverse transcription reaction.
Real-time quantitative PCR was performed on cDNA samples as described by Heid et al.36
to detect mRNA levels.
Primer and probe sequences for Abca1, Abcg5, Abcg8, Bsep (Abcb11), Lxrα (Nr1h3),
Mdr2 (Abcb4), Ntcp (Slc10a1) and Oatp1 (Slc21a1) have been described by Plösch et
al.37. Primer and probe sequences for β-actin, Fxr (Nr1h4), mitochondrial HMG-CoA
synthase (Hmgs), Mdr1a (Abcb1a) and Mdr1b (Abcb1b) have recently been described by
Kok et al.38. The following primer sequences for Mrp2 (Abcc2) were used: sense primer,
5’-GGA TGG TGA CTG TGG GCT GAT-3’; anti-sense primer, 5’-GGC TGT TCT CCC
TTC TCA TGG-3’; and probe 5’-AGC TGC ATC GTC AGG AAT TTC CTC CAC A-3’
(Accession number NM_013806). Primers and detection probes for the gene of interest,
labeled with a fluorescent reporter dye (6-carboxy-fluorescein) and a fluorescent quenching
dye (6-carboxy-tetramethyl-rhodamine) were added. Fluorescence was measured by an
ABI Prism 7700 Sequence Detector v. 1.6 software (Perkin-Elmer Corp., Foster City, CA,
U.S.A.). For every PCR reaction, β-actin was used as the internal control. The cycle number
at the threshold (CT), whereafter the intensity of reporter fluorescent emission increases,
was used to quantitate the PCR product.
Liver plasma membrane isolation
Liver plasma membranes were isolated by density-gradient ultracentrifugation as
described39. The membrane aliquots were frozen and stored until use at -80°C in 10 mM
Tris/HCL (pH 7.4) and 250 mM sucrose, supplemented with complete protease inhibitor
cocktail (Roche). Protein concentrations were determined according to Lowry et al.40 using
bovine serum albumine as a standard. Relative enrichments of Na+ / K+-ATPase as marker
enzyme for the basolateral fraction and alkaline phosphatase as marker enzyme for the
canalicular fraction, i.e., the specific activity of the enzyme in the isolated plasma membrane
preparation divided by the activity in the homogenate, were used to determine the degree
of purification of the isolated membranes in the different experimental groups. Na+ / K+-
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ATPase41 and alkaline phosphatase42 activities were measured.
Western blotting
Approximately 10 µg of protein of plasma membrane fraction of each group, normalized
for enrichment in Na+ / K+-ATPase or alkaline phosphatase, was separated using 4-15%
Tris/HCL ready gradient gels (Bio-Rad laboratories, Hercules, CA, U.S.A.)  and transferred
to nitrocellulose (Amersham Biosciences, Little Chalfont, Bucks., U.K.), using a
tankblotting system (Bio-Rad). The respective anti-Ntcp and anti-Oatp1 immunoglobuline
G (IgG) K4 and K10 were kindly provided by Dr Bruno Stieger and Prof. Peter Meier-Abt
(University Hospital, Zürich, Switserland). Antibodies for detection of Na+ / K+-ATPase
were a kind gift from Dr W. Peters (University Medical Centre, Nijmegen, The Netherlands).
Mouse monoclonal antibody P3II-26, raised against the human MDR3, but also detecting
mouse Mdr2-Pgp, was kindly provided by Dr. J. Scheper (Free University Hospital,
Amsterdam, The Netherlands). The polyclonal antibody raised against Bsep (K12) has
been described before16. The blots were incubated with the first antibody diluted in Tris-
buffered saline containing 5% dried milk powder and 0.1% polyoxyethylene sorbitan
monolaurate (Tween 20; Sigma), washed in Tris-buffered saline / 0.1% Tween 20, incubated
with horseradish peroxidase-labeled donkey anti-rabbit IgG, sheep anti-mouse IgG or rabbit
anti-goat IgG (dilution 1:1000; Amersham Biosciences). Detection was done by the ECL
Western blotting kit (Amersham Biosciences).
Confocal scanning laser microscopy
Localization of Bsep was studied by confocal scanning laser microscopy (CSLM) on 4
µm frozen sections, as described previously16.
Analyses
Bile salts concentrations in plasma and bile were determined by an enzymatic fluorimetic
assay43. Levels of biliary cholesterol, phospholipids and GSH were measured as described
by Kuipers et al.44. Aspartate transaminase (ASAT) and alanine transaminase (ALAT)
activities and total bilirubin concentrations in plasma were determined by routine clinical
chemistry. Total protein content of tissue homogenates was measured using the method
described by Lowry et al.40. Biliary bile salt composition was determined by capillary gas
chromatography as described34 after extraction of the bile salts from bile by use of Sep-
Pack C
18
 cartridges (Waters Associates, Milford, MA, U.S.A.).
Statistical analyses
All results are presented as means ± SD. Differences between the groups were determined
by one-way analysis of variance (ANOVA), with post-hoc comparison by Newman-Keuls
t-test. The level of significance for all statistical analyses was set at P < 0.05. Analyses
were performed using SPSS for Windows software (SPSS, Chicago, IL, U.S.A.).
RESULTS
Animal characteristics
Body and liver weights of untreated wild-type and Pparα (-/-) mice were similar but, as
expected, liver weights were increased significantly upon ciprofibrate treatment in wild-
type mice (Table 1). No increase in liver weight occurred in fibrate-treated Pparα (-/-)
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mice. Aspartate transaminase (ASAT) and alanine transaminase (ALAT) levels in plasma
were slightly increased upon ciprofibrate treatment only in wild-type mice. Plasma bilirubin
and bile salt concentrations did not differ between the groups.
Table 1. Body and liver weights and plasma liver function parameters in untreated and ciprofibrate-
treated wild-type and Pparα (-/-) mice
Strain wild-type Pparα (-/-) wild-type Pparα (-/-)
Ciprofibrate - - + +
Body weight (g) 28.8 ± 1.6 29.1 ± 2.2 28.4 ± 2.6 28.6 ± 3.7
Liver weight (g) 1.3 ± 0.1 1.3 ± 0.2 2.6 ± 0.5b 1.3 ± 0.2a
ASAT (units/L) 113 ± 29 148 ± 89 260 ± 72b 168 ± 96
ALAT (units/L) 49 ± 32 44 ± 20 142 ± 117b 40 ± 18a
Bilirubin (µM) 7 ± 2 7 ± 3 8 ± 4 7 ± 2
Bile salts (µM) 15 ± 11 10 ± 2 21 ± 16 13 ± 3
Values are expressed as means ± SD (n = 10 in all groups). aSignificant difference between wild-
type and Pparα (-/-) mice on the same treatment. bSignificant difference between ciprofibrate-
treated and untreated mice with the same genotype.
Effects of PPARα deficiency and/or ciprofibrate on hepatic transporter mRNA levels
in vivo and in vitro
Real-time quantitative PCR was used to evaluate the expression of transporter genes as
influenced by PPARα deficiency and ciprofibrate in vivo in mice  (Figure 1). Mitochondrial
HMG-CoA synthase (Hmgs), involved in ketogenesis, was used as a PPARα-responsive
gene for comparative purposes45,46. Hmgs mRNA levels increased 4-fold upon ciprofibrate
treatment in wild-type mice but did not change in Pparα (-/-) mice. PPARα deficiency itself
did not affect expression of any of the hepatic transporters studied. Mdr2 was significantly
Figure 1.  Steady-state mRNA levels of Hmgs, Mdr2, Mdr1a, Mdr1b, Bsep, Mrp2, Ntcp and Oatp1
in livers of wild-type and Pparα (-/-) mice after ciprofibrate treatment. Mice were fed either a control
diet or a diet supplemented with 0.05% ciprofibrate for 2 weeks. mRNA was isolated from livers of
wild-type (white bars) and Pparα (-/-) mice (black bars), transcribed into cDNA and subjected to real-
time PCR analysis as described in Materials en Methods. Data represent mean ± SD from four mice
of each group. aSignificant difference between wild-type and Pparα (-/-) mice on the same treatment.
bSignificant difference between ciprofibrate-treated and untreated mice with the same genotype.
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(3-fold) upregulated in wild-type mice treated with ciprofibrate but not in Pparα (-/-) mice.
Likewise, Mdr1a (6-fold) and Mdr1b (11-fold) were upregulated in the wild-type mice
treated with ciprofibrate, but not in Pparα (-/-)  mice. Mrp2 mRNA levels were not
significantly affected by PPARα deficiency and/or ciprofibrate. Bsep and Ntcp mRNA
levels were slightly, though non-significantly, decreased in ciprofibrate-treated wild-type
mice and somewhat induced in ciprofibrate-treated Pparα (-/-) mice. Oatp1 expression, on
the other hand, was drastically decreased in treated wild-type mice but increased in the
treated Pparα (-/-) mice. Expression of three other ABC genes, Abca1, Abcg5 and Abcg8,
encoding transporters recently suggested to play a role in cholesterol secretion, did not
change significantly, although Abcg5/g8 expression tended to be increased in ciprofibrate-
treated wild-type mice (Figure 2). In view of the potential interference of PPARα with
other nuclear receptors involved in control of hepatic transporter expression, we also
evaluated the mRNA levels of a number of these receptors. However, neither ciprofibrate
treatment nor PPARα deficiency affected the mRNA levels of Lxrα , Fxr and Shp in these
experiments (data not shown).
To discriminate between direct PPARα-mediated effects of ciprofibrate on
hepatocellular transporter expression and indirect effects potentially related to drug-induced
metabolic adaptations in the in vivo situation, in vitro studies were conducted. Primary
mouse hepatocytes from wild-type and Pparα (-/-) mice were incubated with ciprofibrate,
WY14,643 or the vehicle (DMSO) for 24 hours and analyzed for expression of transporters
as shown in Figure 3. Ciprofibrate and WY14,643 treatment caused a marked increase
(4-fold) in levels of Hmgs mRNA and a 2.5-fold increase in Mdr2 mRNA levels in
hepatocytes of wild-type mice. Neither of these effects were observed in hepatocytes of
Pparα (-/-) mice, in which the basal expression of Hmgs and Mdr2 was lower than in wild-
type hepatocytes. No effects of ciprofibrate or WY14,643 treatment on mRNA levels of
Mdr1a/b, Bsep, Ntcp, Oatp1, Abca1, Abcg5/g8 or nuclear receptors like Lxrα were observed
(data not shown).
Effects of PPARα deficiency and/or ciprofibrate on hepatic transporter protein levels
in vivo
Protein contents of hepatic transporter proteins were analyzed by Western blotting on
plasma liver membrane fractions (Figure 4). Ciprofibrate treatment resulted in a ~2.5-fold
Figure 2. Steady-state mRNA levels of Abca1, Abcg5 and Abcg8 in livers of wild-type and Pparα
(-/-) mice after ciprofibrate treatment. Mice were fed either a control diet or a diet supplemented with
0.05% ciprofibrate for 2 weeks. mRNA was isolated from livers of wild-type (white bars) and Pparα
(-/-) mice (black bars), transcribed into cDNA and subjected to real-time PCR analysis as described in
Materials en Methods. Data represent mean ± SD from four mice of each group.
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increase of Mdr2-Pgp levels of wild-type mice but not in Pparα (-/-) mice. Protein levels of
Bsep and of the uptake transporters Ntcp and Oatp1 were dramatically decreased in the
treated wild-type mice. This fibrate effect was not seen in Pparα (-/-) mice. Na+ / K+-ATPase
was clearly present, although in somewhat reduced amounts, in liver membrane fractions
of ciprofibrate-treated wild-type mice, showing that the virtual absence of Bsep, Ntcp and
Oatp1 in membrane fractions of these mice is not due to an isolation artifact.
Figure 3. Steady-state mRNA levels of Hmgs and Mdr2 in primary hepatocytes of wild-type and
Pparα (-/-) mice after ciprofibrate and WY14,643 treatment. Mouse hepatocytes were incubated for
24 h, in the presence or absence of 300 µM ciprofibrate or 100 µM WY14,643. mRNA was isolated
from cells of wild-type (white bars) and Pparα (-/-) mice (black bars), transcribed into cDNA and
subjected to real-time PCR analysis as described in Materials en Methods. Data represent mean ±
SD and the experiments were done in triplicate and repeated three times in cells obtained from three
individual mice per genotype. aSignificant difference between hepatocytes of wild-type and Pparα
(-/-) mice. bSignificant difference between ciprofibrate and WY14,643-treated hepatocytes compared
to untreated hepatocytes.
Figure 4. Western blot analysis of Mdr2, Bsep, Ntcp, Oatp1 and Na+ / K+-ATPase (β-subunit) protein
levels in liver plasma membrane fractions of untreated and ciprofibrate-treated wild-type (WT) and
Pparα (-/-) mice. All liver samples (n=3, each from two pooled livers) were tested in the same way,
and similar results were obtained. The appearance of Ntcp protein bands as doublets has been described
previously and is probably due to partial deglycosylation of the protein1. Transport proteins are
indicated at the left side of each blot and apparent molecular masses to the right.
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Localization of Bsep in livers of ciprofibrate-treated mice
Immunofluorescence microscopy on frozen liver sections revealed that, in livers of untreated
wild-type mice, Bsep was exclusively present at the canalicular domain of hepatocytes
and uniformly present across the liver lobule (Figure 5A). In the livers of wild-type mice
Figure 5. Confocal scanning laser microscopy of Bsep protein expression on frozen liver sections of
untreated and ciprofibrate-treated wild-type and Pparα (-/-) mice. Frozen liver sections were stained
with primary antibodies directed against Bsep using K12. (A) wild-type mice: (B) Pparα (-/-) mice:
(C) ciprofibrate-treated wild-type mice: (D) ciprofibrate-treated Pparα (-/-) mice. Arrows depict the
canalicular membrane. Bar is 40 µm.
Table 2. Concentrations of organic solutes in bile and biliary output rates in untreated and ciprofibrate-
treated wild-type and Pparα (-/-) mice
Strain wild-type Pparα (-/-) wild-type Pparα (-/-)
Ciprofibrate - - + +
Bile (mM)
   Bile salts 31.7 ± 11.4 37.4 ± 16.6 6.4 ± 1.9b 35.8 ± 15.9a
   Phospholipids 3.7 ± 0.7 3.8 ± 0.6 0.4 ± 0.3b 3.6 ± 1.2a
   Cholesterol 0.5 ± 0.1 0.5 ± 0.2 0.1 ± 0.05b 0.6 ± 0.2a
   Glutathione 5.7 ± 0.6 5.4 ± 0.7 1.4 ± 0.3b 5.4 ± 0.4a
Bile flow (µl/min/100g) 6.6 ± 1.1 6.7 ± 1.6 30.3 ± 5.0b 7.2 ± 1.1a
Biliary output (nmol/min/100g)
   Bile salts 206 ± 53 239 ± 82 188 ± 66 254 ± 100
   Phospholipids 24.8 ± 6.2 25.4 ± 7.3 10.5 ± 7.2b 25.7 ± 8.9a
   Cholesterol 3.6 ± 0.7 3.7 ± 1.5 2.2 ± 1.5b 4.1 ± 1.5a
   Glutathione 42.1 ± 3.8 40.8 ± 6.5 39.1 ± 12.1 40.3 ± 3.5
Values are expressed as means ± SD ( n = 7-10 per group). Units for bile flow and biliary output are
given per 100 g of body weight. aSignificant difference between wild-type and Pparα (-/-) mice on the
same treatment. bSignificant difference between ciprofibrate-treated and untreated mice with the
same genotype.
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treated with ciprofibrate, Bsep was still expressed canalicularly, but the signal was clearly
reduced (Figure 5C), confirming the results obtained with Western analysis. In the untreated
and treated Pparα (-/-) mice, the localization of Bsep was identical to that in the untreated
wild-type mice (Figure 5B and D). Because of the absence of a suitable antibody, we were
not able to perform immunofluorescence microscopic studies on Mdr2.
Effects of PPARα deficiency and/or ciprofibate on bile flow and bile composition
There were no apparent differences in bile formation between chow-fed wild-type and
Pparα (-/-) mice, showing that PPARα deficiency itself does not affect bile formation in
mice (Table 2). The concentrations of bile salts, phospholipids, cholesterol and glutathione
were significantly reduced in the wild-type mice treated with ciprofibrate. Also the
concentration of acylcarnitines was reduced in this group (data not shown). Interestingly,
bile flow in wild-type mice treated with ciprofibrate was markedly increased compared to
the other groups. In spite of induced Mdr2 Pgp expression, biliary phospholipid and
cholesterol output were significantly decreased in these animals. Analysis of biliary bile
salt composition by gas liquid chromatography did not reveal marked differences between
the groups (Table 3). In all four groups, cholate constituted the major fraction of biliary
bile salts. In ciprofibrate-treated wild-type mice, the relative contents of lithocholate and
chenodeoxycholate were slightly but significantly increased.
Lipid secretion during infusion of TUDC
To gain insight in the physiological consequences of Mdr2 induction and Bsep down-
regulation, we administered increasing amounts of TUDC to ciprofibrate-treated and
untreated wild-type and Pparα (-/-) mice. TUDC is a non-toxic hydrophilic bile salt, which
does not cause cholestasis upon infusion in mice and effectively induces the secretion of
phospholipids and cholesterol into bile. As shown in Figure 6A, bile flow remained markedly
higher in ciprofibrate-treated wild-type mice than in the untreated wild-type and the Pparα
(-/-) mice during the course of the experiment. Biliary bile salt output rates increased to a
similar extent in all groups to levels clearly exceeding endogenous output rates (Figure
6B). This is surprising, in view of the fact that Bsep levels were dramatically decreased in
Table 3. Biliary bile salt composition (as a percentage of the total) in untreated and ciprofibrate-
treated wild-type and Pparα (-/-) mice
Strain wild-type Pparα (-/-) wild-type Pparα (-/-)
Ciprofibrate - - + +
Lithocholate 4.9 ± 1.0 4.9 ± 1.7 11.6 ± 5.0b 4.5 ± 0.9a
Deoxycholate 4.2 ± 1.0 3.5 ± 0.7 1.7 ± 0.9b 4.0 ± 1.8
α-muricholate 5.1 ± 1.4 7.0 ± 1.0 7.1 ± 2.1 6.9 ± 0.9
β-muricholate 8.6 ± 3.9 10.1 ± 2.6 4.1 ± 1.9b 10.7 ± 1.6a
ω-muricholate 6.0 ± 0.9 5.4 ± 2.2 5.6 ± 1.1 4.6 ± 0.5
Chenodeoxycholate 1.7 ± 0.4 1.8 ± 0.5 4.0 ± 0.5b 1.5 ± 0.5a
Cholate 66.5 ± 5.1 63.9 ± 5.0 61.5 ± 5.5 63.5 ± 4.5
Values are expressed as means ± SD (n = 6 in all groups). aSignificant difference between wild-type
and Pparα (-/-) mice on the same treatment. bSignificant difference between ciprofibrate-treated and
untreated mice with the same genotype.
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wild-type mice treated with ciprofibrate. Phospholipid secretion (Figure 6C) decreased
during bile depletion (0-30 min) and the output of phospholipids in wild-type mice treated
with ciprofibrate was lower than in the two other groups despite induction of Mdr2
expression (see also Table 3). During infusion of TUDC at low rates, the phospholipid
secretion was similar in the untreated and fibrate-treated wild-type mice. At 80 min, when
biliary bile salt concentration reached a level of ~30 mM, the secretion of phospholipids
by the ciprofibrate-treated wild-type mice started to increase much more rapidly than in
the untreated wild-type mice, to reach a 2-fold higher rate at the end of the experiment.
The untreated and ciprofibrate-treated Pparα (-/-) mice secreted slightly fewer phospholipids
during the last periods of the infusion. Since the secretion of cholesterol is coupled to that
of phospholipids4 a secretion pattern similar to that of phospholipids was observed for
cholesterol in all groups (Figure 6D).
DISCUSSION
This study demonstrates that the absence of PPARα, a nuclear receptor critically involved
in control of hepatic lipid24 and bile salt metabolism26-28, does not affect the expression of
important transport systems in the liver or bile formation in SV129 mice under normal
chow-fed conditions. Stimulation of PPARα activity with synthetic agonists, however,
Figure 6. Bile flow and biliary bile salt, phospholipid and cholesterol secretion in untreated and
ciprofibrate-treated wild-type and Pparα (-/-) mice during intravenous administration of increasing
amounts of TUDC. Mice were cannulated in the gallbladder and 30 min after starting bile collection,
TUDC was infused via a jugular vein in step-wise increasing dosages, as indicated by the numbers
(nmol/min) in the boxes. ❍ wild-type mice; ● untreated and ciprofibrate-treated Pparα (-/-) mice;ZZ
ciprofibrate-treated wild-type mice. Data represent mean ± SD from four mice of each genotype.
Data for the treated and untreated Pparα (-/-) mice were combined for reasons of clarity: both groups
showed very similar results. (A) bile flow: (B) bile salt secretion: (C) phospholipid secretion: (D)
cholesterol secretion. bSignificant difference between ciprofibrate-treated and untreated mice with
the same genotype.
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resulted in the specific induction of Mdr2 expression and function that was independent
from the rodent-specific PPARα-mediated induction of liver enlargement. In contrast,
increased expression of other members of the B subfamily of ATP-dependent ABC
transporters upon ciprofibrate treatment in vivo, i.e. of Mdr1a and Mdr1b, appeared to be
related to the peroxisome-proliferating capacities or to the metabolic actions of the drug
rather than to direct control of PPARα on expression of these genes.
As expected47, liver weights were significantly increased in ciprofibrate-treated wild-
type mice but not in Pparα (-/-) mice. Liver enlargement in fibrate-treated rodents is due to
both cellular hypertrophy and hyperplasia: the hepatocytes display proliferation of
peroxisomes and, to a lesser extent, of the smooth endoplasmic reticulum31. ASAT and
ALAT activities in plasma were slightly increased in treated wild-type mice, while plasma
bile salt and bilirubin levels remained unaffected. Elevated transaminases may represent a
direct effect of the fibrate on the liver, independent of hepatotoxicity48.
Mdr2 mRNA and Mdr2 Pgp levels were clearly induced in ciprofibrate-treated wild-
type mice and this induction was not seen in the Pparα (-/-) mice. The induction of Mdr2
expression is in accordance with earlier studies, in which mice were treated with different
fibrates, including ciprofibrate22, or other peroxisome proliferators32. From the latter studies,
however, it cannot be concluded whether this fibrate effect is actually PPARα-dependent
or whether it is an aspecific consequence of liver enlargement. The absence of Mdr2
induction in ciprofibrate-treated Pparα (-/-) mice demonstrates PPARα dependency of this
process. Furthermore, our study shows that ciprofibrate and WY14,643 also rapidly induce
Mdr2 mRNA levels in cultured hepatocytes of wild-type mice, but not those of Pparα(-/-)
mice. Thus our combined results firmly establish that the induction of Mdr2 mRNA and
Mdr2 Pgp upon ciprofibrate treatment is directly PPARα-mediated. Two other Mdr genes,
i.e., Mdr1a and Mdr1b, were strongly induced at the mRNA level in vivo. Chianale et al.22
did not observe induction of Mdr1a/Mdr1b expression by fibrates in mice, but these authors
used a Northern blotting procedure which did not allow detection of Mdr1a and Mdr1b
mRNA in normal mouse liver. Also in rats treated with clofibrate49, no induction of
Mdr1a/1b expression was observed. This deviation from our data could be related to the
use of different species and/or treatment strategies. In contrast with the in vivo situation,
in vitro studies did not show induction of Mdr1a and Mdr1b. We propose therefore that
Mdr1a/b induction by fibrates in vivo represents an indirect effect that may be related to
liver hyperplasia or other metabolic changes. Rat Mdr1b is upregulated under various
conditions associated with ‘metabolic stress’ such as partial hepatectomy15 and
lipopolysaccharide treatment16. The expression of Mdr1a is largely unchanged under these
experimental conditions, but is clearly induced by fibrates. The underlying mechanism
remains elusive at the moment.
Surprisingly, protein levels of the canalicular bile salt transporter (Bsep) and of the
major bile salt-uptake systems Ntcp and Oatp1 were drastically decreased in wild-type
mice treated with ciprofibrate, but not in Pparα (-/-) mice. At mRNA level Bsep and Ntcp
expression tended to be decreased in treated wild-type mice, while Oatp1 expression was
dramatically decreased in these animals. Ciprofibrate and WY14,643 did not induce any
change in Bsep, Ntcp and Oatp1 mRNA levels in cultured hepatocytes. Immunofluorescence
studies confirmed that Bsep was down-regulated in ciprofibrate-treated wild-type mice
and revealed that Bsep was still mainly localized canalicularly under these conditions.
Despite the fact that Bsep, Ntcp and Oatp1 protein levels were all down-regulated, plasma
bile salt concentrations and biliary bile salt secretion rates were hardly affected, even
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during the course of supraphysiological TUDC infusions. Recent studies by Meerman et
al.50 have shown that in fch/fch mice, in which Ntcp and Oatp1 are also strongly down-
regulated, the majority of intravenously administered radiolabeled taurocholate was present
in liver and bile within 30 min after injection, possibly indicative for taurocholate uptake
by the liver via alternative mechanisms. Unaffected biliary bile salt secretion in the face of
strongly reduced Bsep levels probably illustrates the overcapacity of this excretory system.
We speculate that an excessive amount of Bsep is present in mouse liver under ‘normal
conditions’ and that the decreased amounts of Bsep in fibrate-treated wild-type mice are
still able to fully accommodate bile salt transport. Alternatively, it has recently been shown51
that Bsep-deficient mice are able to secrete limited amounts of primary bile salts into bile.
Therefore, alternative mechanisms for biliary bile salt secretion should be considered.
 Despite the marked alterations in transporter expression upon ciprofibrate treatment
of wild-type mice, hepatobiliary bile salt flux remained unaffected but bile flow was strongly
increased. This latter effect was not seen in ciprofibrate-treated Pparα (-/-) mice. The cause
of the increased bile flow is currently unknown, but may be related to excretion into bile
of PPARα-dependent ciprofibrate metabolites or other metabolites/solutes generated by
PPARα activation. The biliary concentrations of bile salts, phospholipids, cholesterol and
glutathione were markedly reduced in treated wild-type mice. For bile salts and glutathione,
this reduction was probably secondary to the increased bile flow. However, when corrected
for bile flow, phospholipid and cholesterol output rates remained significantly reduced in
fibrate-treated wild-type mice compared to untreated controls. This despite the fact that
Mdr2 Pgp levels were clearly increased. The determinants of biliary phospholipid (and
cholesterol secretion) are (i) the actual biliary bile salt concentration, which is partly
determined by the magnitude of the bile acid-independent flow (BAIF)52, (ii) the biliary
bile salt composition, (iii) the presence of non-bile salt organic anions in bile4 and (iv) the
Mdr2 Pgp activity5. The biliary bile salt concentration was strongly reduced by ciprofibrate
in wild-type mice, due to an unexplained increase of the bile acid-independent flow. A
high bile acid-independent flow influences the ‘exposure time’ of the bile canalicular
membrane to the intracanalicular bile salts and thereby reduces the efficacy of these bile
salts to induce the secretion of lipids. Biliary bile salt composition was similar in all groups
of mice and, therefore, can not be responsible for impaired phospholipid and cholesterol
secretion in ciprofibrate-treated wild-type mice. The lowered phospholipid secretion under
basal conditions can theoretically be due to an ‘uncoupling’ effect of ciprofibrate-metabolites
into bile53. We infused increasing amounts of TUDC to see if Mdr2 Pgp was indeed
functionally upregulated in ciprofibrate-treated wild-type mice. Figure 5 shows that, at a
certain timepoint, the fibrate-treated wild-type mice started to secrete much more
phospholipids and cholesterol into bile than the untreated wild-type and Pparα (-/-) mice
did. At the point of onset of phospholipid hypersecretion, the biliary bile salt concentration
was about 30 mM. It therefore seems appropriate to suggest that a certain threshold bile
salt concentration is needed for ‘optimal’ secretion of phospholipids by Mdr2 Pgp. The
secretion of cholesterol is coupled to that of phospholipids4 and for cholesterol a similar
pattern of secretion was observed during these experiments. With these infusion studies,
we have unequivocally demonstrated a functional induction of Mdr2 Pgp by ciprofibrate
in mice. A role of Abcg5/g8 in control of cholesterol secretion is emerging on the basis of
studies in mice overexpressing both halftransporters7. In view of the modest changes seen
in their expression, Abcg5/g8 are unlikely responsible for the observed changes in biliary
cholesterol secretion.
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Recent studies indicate a multifactorial regulation of Mdr2 expression in rodents. An
increase in Mdr2 mRNA and protein levels has been detected in rats treated with statins19,20.
Statins cause a transient state of cellular cholesterol deprivation, resulting in enhanced
transcription of sterol-regulated genes by sterol regulatory element-binding proteins
(SREBPs). SREBPs possibly play a role in regulation of Mdr2 gene expression54. Bile
salts may also be involved in the regulation of Mdr2 expression. Bile diversion in rats
lowers Mdr2 mRNA levels55, while bile salt feeding has the opposite effect18. Bile salts
presumably do not play a role in our study, because the bile salt flux did not differ between
the groups. Finally, recent work from our laboratory has shown that insulin deficiency is
associated with strongly induced Mdr2 expression in rats21. Based on our observation that
PPARα deficiency per se did not alter Mdr2 expression, we propose that PPARα-mediated
control of Mdr2 is of physiological relevance only under conditions of metabolic stress
associated with PPARα activation, e.g., during fasting38 and other conditions associated
with enhanced free fatty acid flux towards the liver such as diabetes21.
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